We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjuvant Colon Cancer w/ ELOXatin®/5 FU Based Regimen: ACCELOX

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01310972
First Posted: March 9, 2011
Last Update Posted: February 25, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
King Faisal Specialist Hospital & Research Center
  Purpose
Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Condition Intervention
Colon Cancer Other: Registry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Adjuvant Colon Cancer With ELOXatin®/5 FU Based Regimen: ACCELOX

Further study details as provided by King Faisal Specialist Hospital & Research Center:

Primary Outcome Measures:
  • OS, PFS, DFS [ Time Frame: For the duration of the experiment ]

Enrollment: 6
Study Start Date: September 2007
Study Completion Date: September 2007
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Registry
    Registry
Detailed Description:
It's a study of adjuvant colon carcinoma using ELOXatin/5-FU based chemotherapeutic regimen called ACCELOX as a definitive curative therapy.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   14 Years to 85 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Colon Cancer Registry
Criteria

Inclusion Criteria:

  • Patients with Adjuvant Colon Cancer

Exclusion Criteria:

  • Patients with diagnosis other than Colon Cancer.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01310972


Locations
Saudi Arabia
Kfsh & Rc
Riyadh, Saudi Arabia
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Investigators
Principal Investigator: Al Jubran, M.D. KFSH & RC
  More Information

Responsible Party: King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01310972     History of Changes
Other Study ID Numbers: RAC# 2071-027
RAC# 2071-027 ( Other Identifier: KFSH&RC IRB )
First Submitted: March 6, 2011
First Posted: March 9, 2011
Last Update Posted: February 25, 2016
Last Verified: December 2011
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by King Faisal Specialist Hospital & Research Center:
Adjuvant Colon Cancer

Additional relevant MeSH terms:
Colonic Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Oxaliplatin
Antineoplastic Agents